PRN Antipsychotic Selection for Patients on Invega (Paliperidone)

Primary Recommendation: Olanzapine

The American College of Cardiology recommends olanzapine as the preferred PRN agent for patients taking Invega, due to its consistency with atypical antipsychotic therapy, safest cardiac profile, and lowest risk of extrapyramidal symptoms 1
For acute agitation, start with olanzapine 2.5-5 mg orally, with the option to repeat after 2 hours if needed, as recommended by the American Psychiatric Association 1
Use olanzapine 10 mg IM if oral administration is not feasible in severely agitated patients, according to the American Medical Association 1
Reduce doses in older or frail patients to minimize risk of oversedation and orthostatic hypotension, as suggested by the European Society of Cardiology 2

For cooperative patients with agitation, consider combining the scheduled paliperidone with lorazepam 1-2 mg as the PRN agent, which produces similar improvement to antipsychotic combinations with less cardiac risk, as recommended by the National Institute of Mental Health 1
Lorazepam 1 mg subcutaneous or IV can be used as a crisis medication for severe agitation, with lower doses (0.5-1 mg) in older or frail patients, according to the American Academy of Emergency Medicine 2

Avoid combining olanzapine with benzodiazepines due to risk of oversedation and respiratory depression, as warned by the Food and Drug Administration 2
Obtain baseline ECG if cardiac risk factors are present, as both paliperidone and any added antipsychotic can prolong QTc interval, as recommended by the American Heart Association 1
Avoid haloperidol as a PRN agent in patients on paliperidone, as it carries higher QTc prolongation risk and significantly more extrapyramidal symptoms, according to the American Psychiatric Association 1

Monitor for movement disorders at every clinical contact, as these predict poor long-term adherence, as suggested by the National Institute of Neurological Disorders and Stroke 1
Watch for orthostatic hypotension, especially when initiating olanzapine in combination with paliperidone, as warned by the European Society of Cardiology 2, 1